Some Cancer Drugs May Boost Arthritis Risk

A class of cancer immunotherapy drugs may increase the risk of developing joint and tissue diseases, such as arthritis.

Researchers at the Johns Hopkins University School of Medicinein Baltimore  have discussed 13 case reports of patients who were taking Yervoy (ipilimumab) and/or Opdivo (nivolumab) between 2012 and this year and developed new-onset arthritis or sicca syndrome, a set of autoimmune conditions causing dry eyes and mouth, including Sjogren’s syndrome.

Yervoy and Opdivo are in a class of cancer drugs known as checkpoint inhibitors. For patients with melanoma, a type of skin cancer, the drugs are taken together. A third checkpoint inhibitor on the market is Keytruda (pembrolizumab). Opdivo and Keytruda can also be used to treat a type of lung cancer.

“In 2015, our rheumatology clinic started getting more and more referrals from our oncology department to evaluate patients treated with immunotherapies,” lead study author Laura C. Cappelli, MD, a rheumatologist at Johns Hopkins, said in a statement. “And the patients we saw had very severe, highly inflammatory arthritis. They needed even higher doses of steroids to control their symptoms compared to what is needed in other forms of inflammatory arthritis, like rheumatoid arthritis.”

However, the researchers noted that the 13 patients on checkpoint inhibitors represented only 1.5% of the patients between 2012 and 2016 who were taking one or both of the drugs at the Kimmel Cancer Center. Also, additional research is needed to determine a cause-and-effect relationship.

Cappelli said she wants the case reports, which were published in the Annals of the Rheumatic Diseases, to raise awareness among both patients and doctors of the side effects that may occur with these drugs.

“It is important when weighing the risk-benefit ratio of prescribing these drugs,” she said. “And it’s important for people to be on the lookout for symptoms so they can see a rheumatologist early in an effort to prevent or limit joint damage.”


Jonathan Block

Jonathan Block

Jonathan Block is a freelance writer and former MedShadow content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including BioCentury, The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

FDA Recalls Metformin and NP Thyroid

FDA Recalls Metformin and NP Thyroid

The FDA has issued a recall of two drugs–NP Thyroid and Metformin–after testing revealed that they weren’t up to code. Read more below, and if you’re taking either medication, please be sure to contact your doctor for how to continue treatment responsibly.  NP Thyroid Recalled Thirteen lots of NP Thyroid,…

Can Convalescent Plasma Treat COVID-19 Patients?

Can Convalescent Plasma Treat COVID-19 Patients?

One of the most promising treatments for COVID-19 is convalescent plasma, a component of blood. People who have been infected with the virus and are now healthy have developed COVID-19-fighting antibodies, which, the theory is, can be given to people currently sick with COVID-19 so that those antibodies can boost…

  • Advertisement